SIDEBAR: All Eyes on Trials of IV vs IP Chemotherapy for Ovarian Cancer

Get Permission

The positive findings from the NOVEL trial add to the debate about how intravenous (IV) chemotherapy stacks up against intraperitoneal (IP) chemotherapy when treating ovarian cancer and the role of dose-dense approaches in general, according to Jonathan S. Berek, MD, of the Stanford Women’s Cancer Center, Stanford, California.

A host of ongoing trials—GOG0252, GOG0262, ICON8, MITO 7, and iPOCC—are sorting out the impact of the route of administration and specific drugs, in addition to dose-dense strategies. “In the next 2 to 3 years, we are going to start to see mature data that will help us decide what’s best for our patients,” he predicted.

“What should we do now for our patients? I think you have to individualize,” Dr. Berek recommended. “I have been doing IP therapy for several decades…, but certainly giving a dose-dense regimen is a lot easier than maintaining intraperitoneal catheters.”  

Related Articles

Major Strides Seen in Treatment of Gynecologic Cancers

Research reported at this year’s ASCO Annual Meeting shows major strides in treating ovarian and cervical cancers, suggesting the potential of new agents and adding evidence in areas where optimal management is unclear, according to Jonathan S. Berek, MD, of the Stanford Women’s Cancer Center,...

SIDEBAR: Future of PARP Inhibitors in Ovarian Cancer Hangs in Balance

"It’s become clear that the PARP inhibitors in general … are active in this disease, and we are just trying to find out the level of activity and … get to the point hopefully where at least one of these agents will be approved for use” in ovarian and related cancers, commented Jonathan S. Berek,...




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.